Bioverativ

ENJAYMO

Manufacturer:

Bioverativ

Enjaymo HCPCS:

C9094

HCPCS Code Descriptor:

Inj, sutimlimab-jome, 10 mg

Category:

C Code

Enjaymo NDCs:

No actively aligned NDCs found

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Enjaymo CPT Codes:

Potential CPT administration codes for Enjaymo can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Enjaymo:

ENJAYMO is a Hematology drug manufactured by Bioverativ and administered via the Intravenous route of administration. The C Code: C9094 is aligned to the drug ENJAYMO.

ACCESS PRICING AND MORE BY REGISTERING

C9094 Added Date:

July 1, 2022

C9094 Effective Date:

October 1, 2022

C9094 Termination Date:

September 30, 2022

We have not yet identified a manufacturer source of Enjaymo billing and coding information.
Enjaymo patient assistance information can be found through ENJAYMO Patient Solutions at the URL: https://www.enjaymo.com/support-and-resources/patient-solutions
ENJAYMO prescribing information can be found at the link below:
Information regarding ENJAYMO’s side effects can be found at MedlinePlus